Medicine Press release

Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Bio B.V., a wholly owned subsidiary of NEC Corporation, a leader in IT, network and AI technologies, announce the signing of a license agreement to advance the clinical development of TG4050, an individualized neoantigen therapeutic vaccine (INTV) in the adjuvant treatment of resected HPV-negative head and neck cancer.
More info..

Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Bio B.V., a wholly owned subsidiary of NEC Corporation, a leader in IT, network and AI technologies, announce the signing of a license agreement to advance the clinical development of TG4050, an individualized neoantigen therapeutic vaccine (INTV) in the adjuvant treatment of resected HPV-negative head and neck cancer.
More info..

Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Bio B.V., a wholly owned subsidiary of NEC Corporation, a leader in IT, network and AI technologies, announce the signing of a license agreement to advance the clinical development of TG4050, an individualized neoantigen therapeutic vaccine (INTV) in the adjuvant treatment of resected HPV-negative head and neck cancer.
More info..

Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Bio B.V., a wholly owned subsidiary of NEC Corporation, a leader in IT, network and AI technologies, announce the signing of a license agreement to advance the clinical development of TG4050, an individualized neoantigen therapeutic vaccine (INTV) in the adjuvant treatment of resected HPV-negative head and neck cancer.
More info..

OMRON Healthcare Co., Ltd. today announced the launch of a randomized controlled trial in collaboration with the University of California, San Francisco (UCSF) to evaluate a new model for the early detection of atrial fibrillation (AFib) in hypertension patients using home blood pressure monitoring.
More info..

OMRON Healthcare Co., Ltd. today announced the launch of a randomized controlled trial in collaboration with the University of California, San Francisco (UCSF) to evaluate a new model for the early detection of atrial fibrillation (AFib) in hypertension patients using home blood pressure monitoring.
More info..

Across the landscape of global biotech companies, the appointment of a senior executive often serves as a "barometer"-offering insights into a company's pipeline potential and reflecting how industry veterans gauge the sector's future.
More info..

Across the landscape of global biotech companies, the appointment of a senior executive often serves as a "barometer"-offering insights into a company's pipeline potential and reflecting how industry veterans gauge the sector's future.
More info..

Across the landscape of global biotech companies, the appointment of a senior executive often serves as a "barometer"-offering insights into a company's pipeline potential and reflecting how industry veterans gauge the sector's future.
More info..

Eisai Co., Ltd. and MSD K.K., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, announced today that an application for LENVIMA(R) (lenvatinib), an orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, has been submitted in Japan for the additional dosage and administration in combination with WELIREG(R) (belzutifan), the first-in-class oral hypoxiainducible factor-2 alpha (HIF-2a) inhibitor from MSD, for the treatment of unresectable or metastatic renal cell carcinoma that has progressed after chemotherapy.
More info..